Back to search

Efficacy and Safety of Nitazoxanide for Post Exposure Prophylaxis of COVID-19 in Household Contacts

NCT04788407

PHASE4INTERVENTIONAL
Fundación Huésped
456 participants
Started 2020-12-01 · Completed 2022-04-30
Status: Unknown (as of 12-23-2025)

Conditions

Covid19SARS-CoV-2 InfectionHouseholds Contacts

Interventions

DRUG: NitazoxanideDRUG: Placebo

Linked Papers (from SciSciNet-V2)

Total Papers0
Background
0
Result
0
Derived
0
Unknown
0
View on ClinicalTrials.gov

Brief Summary

The primary objective of this study is to evaluate the efficacy of the drug nitazoxanide 500 mg, administered three times a day, in relation to placebo in preventing the development of COVID-19 in household contacts of patients diagnosed with the disease.

No papers linked to this trial in SciSciNet

Visit ClinicalTrials.gov for more information about this study